# Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

> **NCT05122091** · PHASE2 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 53 (estimated)

## Conditions studied

- Gastric Cancer
- GastroEsophageal Cancer
- Fruquintinib
- SOX

## Interventions

- **DRUG:** Fruquintinib + SOX

## Key facts

- **NCT ID:** NCT05122091
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-05
- **Primary completion:** 2024-11-05
- **Final completion:** 2024-11-30
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05122091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05122091, "Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05122091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*